The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and soc ....
07 Oct 2019
Cancer - Strategy for affordable care
4SC AG (VSC:FRA), 0 | Abbott Laboratories (0Q15:LON), 0 | AbbVie, Inc. (0QCV:LON), 0 | Affimed N.V. (0HL9:LON), 0 | Agilent Technologies, Inc. (0HAV:LON), 0 | Alphabet Inc. Class A (0RIH:LON), 15,440 | Amgen Inc. (0R0T:LON), 26,550 | AstraZeneca PLC (AZN:LON), 10,953 | Biocartis Group NV (BCART:BRU), 0 | Bristol-Myers Squibb Company (BMYS:WBO), 0 | Elekta AB Class B (EJXB:FRA), 0 | Exact Sciences Corporation (EXK:FRA), 0 | GSK plc (GSK:LON), 1,600 | Illumina, Inc. (0J8Z:LON), 0 | Innate Pharma SA Class A (IPH:PAR), 0 | Intuitive Surgical, Inc. (0R29:LON), 0 | Ion Beam Applications SA (IBAB:BRU), 0 | Johnson & Johnson (0R34:LON), 14,650 | MDxHealth S.A. (0O8G:LON), 0 | MediGene AG (0QGJ:LON), 0 | Medtronic Plc (0Y6X:LON), 0 | Merck KGaA (MRCK:WBO), 0 | Myriad Genetics, Inc. (0K3W:LON), 0 | NanoString Technologies, Inc. (NSTGQ:OTC), 0 | Novartis AG (0QLR:LON), 0 | Oncocyte Corporation (0KCC:LON), 0 | Pfizer Inc. (0Q1N:LON), 2,580 | RaySearch Laboratories AB Class B (0GRZ:LON), 0 | Roche Holding Ltd Dividend Right Cert. (RHO5:ETR), 0 | Sanofi (SANO:WBO), 0 | SEATTLE GENETICS (SGEN:NYSE), 0 | Thermo Fisher Scientific Inc. (0R0H:LON), 0 | Transgene SA (0OCQ:LON), 0 | Veracyte Inc (12V:BER), 0 | Volitionrx Limited (VNRX:ASE), 0 | Xencor, Inc. (XE9:BER), 0 | Epigenomics AG (0QXH:LON), 0 | Immutep Ltd (IMM:ASX), 0 | QIAGEN NV (0RLT:LON), 0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cancer - Strategy for affordable care
4SC AG (VSC:FRA), 0 | Abbott Laboratories (0Q15:LON), 0 | AbbVie, Inc. (0QCV:LON), 0 | Affimed N.V. (0HL9:LON), 0 | Agilent Technologies, Inc. (0HAV:LON), 0 | Alphabet Inc. Class A (0RIH:LON), 15,440 | Amgen Inc. (0R0T:LON), 26,550 | AstraZeneca PLC (AZN:LON), 10,953 | Biocartis Group NV (BCART:BRU), 0 | Bristol-Myers Squibb Company (BMYS:WBO), 0 | Elekta AB Class B (EJXB:FRA), 0 | Exact Sciences Corporation (EXK:FRA), 0 | GSK plc (GSK:LON), 1,600 | Illumina, Inc. (0J8Z:LON), 0 | Innate Pharma SA Class A (IPH:PAR), 0 | Intuitive Surgical, Inc. (0R29:LON), 0 | Ion Beam Applications SA (IBAB:BRU), 0 | Johnson & Johnson (0R34:LON), 14,650 | MDxHealth S.A. (0O8G:LON), 0 | MediGene AG (0QGJ:LON), 0 | Medtronic Plc (0Y6X:LON), 0 | Merck KGaA (MRCK:WBO), 0 | Myriad Genetics, Inc. (0K3W:LON), 0 | NanoString Technologies, Inc. (NSTGQ:OTC), 0 | Novartis AG (0QLR:LON), 0 | Oncocyte Corporation (0KCC:LON), 0 | Pfizer Inc. (0Q1N:LON), 2,580 | RaySearch Laboratories AB Class B (0GRZ:LON), 0 | Roche Holding Ltd Dividend Right Cert. (RHO5:ETR), 0 | Sanofi (SANO:WBO), 0 | SEATTLE GENETICS (SGEN:NYSE), 0 | Thermo Fisher Scientific Inc. (0R0H:LON), 0 | Transgene SA (0OCQ:LON), 0 | Veracyte Inc (12V:BER), 0 | Volitionrx Limited (VNRX:ASE), 0 | Xencor, Inc. (XE9:BER), 0 | Epigenomics AG (0QXH:LON), 0 | Immutep Ltd (IMM:ASX), 0 | QIAGEN NV (0RLT:LON), 0
- Published:
07 Oct 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
82
The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and soc ....